NCT00575185View on ClinicalTrials.gov

Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

February 28, 2010

Conditions
Infectious Mononucleosis
Interventions
DRUG

Valomaciclovir

4 grams orally of valomaciclovir (2 grams BID) for 21 days.

DRUG

placebo

Placebo tablets orally twice daily for 21 days.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

Sponsors

Collaborators (1)

Epiphany Biosciences
All Listed Sponsors
collaborator

Epiphany Biosciences

INDUSTRY

lead

University of Minnesota

OTHER